Vertex Pharmaceuticals, Inc.

Jason McCartney

Mark Thomas Miller

Jinglan Zhou

Sara Sabina Hadida Ruah

Brian Richard Bear

Fredrick Van Goor

Peter D J Grootenhuis

Corey Don Anderson

Sara Sabina Hadida-Ruah

Peter Diederik Jan Grootenhuis

Peter Grootenhuis

Thomas Cleveland

Bryan A Frieman

Jeremy J Clemens

Vijayalaksmi Arumugam

Johnny Uy

Haripada Khatuya

Andreas Peter Termin

Timothy Richard Coon

Prasuna Paraselli

Paul Krenitsky

Fabrice Jean Denis Pierre

Matthew Michael Hamilton

Pramod Virupax Joshi

Xiaoqing Yang

Alexander Russell Abela

Mehdi Michel Djamel Numa

Ashvani Singh

Vito Melillo

Raymond Stanley Gross

Fabrice Pierre

Anna Hazlewood

Sara E Swift

Mehdi Michel Jamel Numa

Alina Silina

David Andrew Siesel

Hayley Marie Binch

Robert Michael Hughes

Ali Keshavarz-Shokri

Yi Shi

Gulin Erdogan Marelius

Paul Angell

Muna Shrestha

Minson Baek

Erica Lynn Conroy

Anton V Gulevich

Clara Kuang-Ju Hsia

Ping Kang

Timothy Alcacio

Chun-Chieh Lin

Georgia McGaughey Nicholls

Beili Zhang

Brett Bradley Busch

Edward Adam Kallel

Frederick Van Goor

Kathy Stavropoulos

Lori Ann Ferris

Mehdi Numa

Timothy John Young

Benjamin Joseph Littler

John E Cochran

Nicole Hilgraf

Ales Medek

Joseph Pontillo

Weichao George Chen

Michael Waldo

Kevin Gagnon

Sara Hadida Ruah

Armando Urbina

Carl Zwicker

Senait G Ghirmai

Licong Jiang

Fred Van Goor

Jicong Li

Sunny Abraham

James Philip Johnson

Sarah S Hadida Ruah

Sarah Hadida-Ruah

Carl V Vogel

Rachel McAuley-Aoki

Jennifer Lu

Yoshihiro Ishihara

Joe Anh Tran

Fredrick VanGoor

Anna Hazelwood

Mehdi Michael Djamel Numa

Jennings Franklin Worley, Iii

Jaclyn Chau

Timothy A Dwight

Fredrick F Van Goor

Paul John Krenitsky

Peter DJ Grootenhuis

Anna R Hazlewood

Ashvani K Singh

Mark Miller

Ruah Sara Hadida

Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.

Cystic fibrosis transmembrane conductance regulator modulating agents

Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Indole derivatives as CFTR modulators

Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Crystalline forms of CFTR modulators

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R, R, R, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Modulators of cystic fibrosis transmembrane conductance regulator

The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.

Process of making CFTR modulators

Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ('CFTR'). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Modulators of ATP-binding cassette transporters

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof. 

Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators.

Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Growing community of inventors

Cardiff by the Sea, CA, United States of America

Jason McCartney